QTZM
Quantumzyme Corp.3.1800
+0.0200+0.63%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
123.90MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Quantum Genesis AI Corp posted no sales for Q2 FY2026 ended January 31, 2026, with operating loss shrinking to $1,382 from $24,534 y/y while net loss exploded to $4.3M from $29,806, driven by a $4.3M loss on debt conversion after issuing 2,010,000 shares to settle $76K notes plus interest. Cash dwindled to $59 from $584 at July 31, 2025, after $43,810 used in operations offset by $43K new notes at 10%; notes payable eased to $232K. Stockholders' deficit narrowed slightly to $418K. Controls remain ineffective due to limited resources. Debt funding keeps it afloat, barely.
8-K
Name change to QGAI approved
Quantumzyme Corp. amended its Articles of Incorporation, changing its name to Quantum Genesis AI Corp., effective February 11, 2026, after 79.56% shareholder approval on November 30, 2025. FINRA approved the name and symbol switch to QGAI, effective at market open February 17, 2026. No impact on shares or shareholder rights. Purely cosmetic.
8-K
Name change to Quantum Genesis AI
Quantumzyme Corp. amended its Articles of Incorporation on November 30, 2025, to rebrand as Quantum Genesis AI Corp., approved by board and majority shareholder consent. Filing with Nevada awaits Schedule 14C's 20-day period; FINRA review pending for new ticker. No impact on shares or shareholder rights. Name signals AI pivot.
10-Q
Q1 FY2026 results
Quantumzyme posted no sales for Q1 FY2026 ended October 31, 2025, trimming its net loss to $49,868 from $65,523 y/y while operating loss eased to $39,196 from $60,934 on lower professional fees. Interest expense doubled to $10,672, widening the gap between operating and net loss. Cash dwindled to $184 from $584 q/q amid $19,913 operating burn, offset by $19,513 in new notes at 10% that pushed total debt to $268,594; related-party dues sit at $16,602. Notes due on demand. Controls ineffective due to limited resources. Going concern in doubt.
10-K
FY2025 results
Quantumzyme Corp posted a FY2025 net loss of $199K, up from $179K in FY2024, on zero revenue as the development-stage biotech advances its first enzyme for ibuprofen API production. Operating expenses climbed to $181K from $164K on higher professional fees, while other expenses hit $19K from added debt interest. Cash burn reached $125K, offset by $126K in stock issuance financing, leaving a $441K liability pile against $584 in assets. Single employee Kulkarni anchors operations from a $500/month shared office. Dependence on this sole executive risks disrupting quarterly progress.
IPO
Sector
Industry
AAQL
Antiaging Quantum Living Inc.
0.59+0.00
ETHZ
ETHZilla Corporation
6.85-0.10
EXOZ
eXoZymes Inc.
12.52-1.78
IMA
ImageneBio, Inc.
6.25+0.08
NVZMF
NOVONESIS A S
60.05-1.72
QNTM
Quantum Biopharma Ltd.
8.65+0.90
QS
QuantumScape Corporation
10.84+0.01
QSI
Quantum-Si Incorporated
1.22-0.01
RVRC
REVIUM RECOVERY INC
0.52+0.00
SQM
Sociedad Quimica y Minera S.A.
64.17-0.80